TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00386490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: capsule for oral administration
Study: NCT02394808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
Study: NCT03559192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67953964
Description: JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as 2 capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as 2 capsules orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as 2 capsules orally once daily.
Study: NCT04220385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
Study: NCT02119364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Working memory training
Description: The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
Study: NCT01497158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help brochure
Description: Self help brochure given at baseline visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help brochure
Description: Self help brochure given at baseline visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker feedback
Description: Biomarker feedback from urine of adult non-smoker in the home.
Study: NCT01783262

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK
Description: an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK
Study: NCT02803255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAHI Exo-II

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAHI Exo-II
Study: NCT02304679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-inclusion questionnaires
Description: (Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pre-inclusion questionnaires
Description: (Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 month of PDE5i treatment
Description: 5 mg Tadalafil per day for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 month of PDE5i treatment
Description: 5 mg Tadalafil per day for 1 month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDE5i follow-up questionnaires
Description: (Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PDE5i follow-up questionnaires
Description: (Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled
Study: NCT01905670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiCS-LV system
Description: Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
Study: NCT02835677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Education and skills building, including problem solving, cognitive restructuring, and stress management
Study: NCT04141215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIOBank bone paste
Description: BIOBank bone paste (PPT322)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BIOBank cortico-cancellous bone powder
Description: BIOBank cortico-cancellous bone powder (PPT6)
Study: NCT03685370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOS
Description: placement of epidural catheters with LOS technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-ray placement
Description: placement of epidural catheters with x-ray guide
Study: NCT03277703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population
Study: NCT02746354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MySupport tool
Description: Utilization of the MySupport tool, a tailored patient-centered assessment
Study: NCT04732819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High touch multi-pronged behavioral intervention
Description: In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team.
Study: NCT02781454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Study: NCT02304679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion questionnaires
Description: (Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inclusion questionnaires
Description: (Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit.
Study: NCT02781454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01866761

Intervention type: PROCEDURE
Intervention: Periodontal treatment
Study: NCT00585052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Lovastatin, 80 mg, po, daily will be self-administered by the subject.
Study: NCT01522794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-H94
Description: single i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: single i.v. infusion
Study: NCT00374192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 3 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02944760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Light Therapy
Description: The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-Level Light Therapy
Description: The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
Study: NCT01769053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Variable Ventilation
Study: NCT00087698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
Study: NCT00561522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No other preventive treatment
Description: No other preventive treatment
Study: NCT01484457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop session
Description: Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose \< 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia.
Study: NCT01080417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil Capsule 250 mg
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil Capsule 250 mg
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT04029207

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Abdominal, operative delivery of the fetus
Study: NCT02118155

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Connective tissue graft
Description: Periodontal surgical technique to treat gingival recessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: Periodontal surgical technique to treat gingival recessions
Study: NCT02054923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of routine videorecording
Description: All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
Study: NCT04155476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Topical Product
Description: application of NG topical to dorsals pedis and posterior tibial arteries.
Study: NCT02054923

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No routine videorecording
Description: Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
Study: NCT04155476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin Topical Product
Description: application of NG topical to dorsals pedis and posterior tibial arteries.
Study: NCT02422979

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
Study: NCT03662282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
Study: NCT00755170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
Study: NCT02913963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Kinesio Taping
Description: Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
Study: NCT02221973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sterols and hawthorn powder
Description: there are two dose level of sterols (1.2g/d; 1/8g/d)
Study: NCT00303758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT03179436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
Study: NCT02221973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sterols and hawthorn powder
Description: there are two dose level of sterols (1.2g/d; 1/8g/d)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sterols and hawthorn powder
Description: there are two dose level of sterols (1.2g/d; 1/8g/d)
Study: NCT04035889

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
Study: NCT03179436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.